Published in Clin Exp Rheumatol on August 12, 2005
Antifolate/antiproliferative therapy in rheumatoid arthritis. Clin Exp Rheumatol (2005) 0.75
A pigment-binding protein essential for regulation of photosynthetic light harvesting. Nature (2000) 6.97
Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell (1982) 6.93
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature (1982) 6.09
Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci U S A (1979) 5.32
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature (1981) 4.72
Keratin cytoskeletons in epithelial cells of internal organs. Proc Natl Acad Sci U S A (1979) 3.45
Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation (1999) 3.35
Three different human tumor cell lines contain different oncogenes. Cell (1981) 2.77
Rat model of arterial thrombosis induced by ferric chloride. Thromb Res (1990) 2.32
Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell (1982) 2.22
Trophic conversion of an obligate photoautotrophic organism through metabolic engineering. Science (2001) 2.10
Presentation of striatal hyperintensity on T1-weighted MRI in patients with hemiballism-hemichorea caused by non-ketotic hyperglycemia: report of seven new cases and a review of literature. J Neurol (2001) 2.02
Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem (2000) 1.91
Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release (2001) 1.85
The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. J Virol (1999) 1.76
Interferon-gamma induces downregulation of Tangier disease gene (ATP-binding-cassette transporter 1) in macrophage-derived foam cells. Arterioscler Thromb Vasc Biol (2000) 1.74
Discovery and validation of blood biomarkers for suicidality. Mol Psychiatry (2013) 1.69
Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A (1983) 1.67
Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest (1984) 1.65
Oncogene from human EJ bladder carcinoma is located on the short arm of chromosome 11. Science (1983) 1.58
Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J Biol Chem (1984) 1.56
Long-term human peripheral blood monocyte cultures: establishment, metabolism and morphology of primary human monocyte-macrophage cell cultures. Immunology (1979) 1.55
MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging (2001) 1.51
Morphometric variations of the lumbar vertebrae between Chinese and Indian adults. Acta Anat (Basel) (1992) 1.46
Establishment and characterization of a new human hepatocellular carcinoma cell line. In Vitro (1984) 1.43
Preferred translation of human hepatitis B virus polymerase from core protein- but not from precore protein-specific transcript. J Virol (1990) 1.43
Photoprotection in a zeaxanthin- and lutein-deficient double mutant of Arabidopsis. Photosynth Res (2001) 1.42
Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein. J Virol (2000) 1.41
Subtype-independent immature secretion and subtype-dependent replication deficiency of a highly frequent, naturally occurring mutation of human hepatitis B virus core antigen. J Virol (1999) 1.39
A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem (1992) 1.38
Localization, interaction, and RNA binding properties of the V(D)J recombination-activating proteins RAG1 and RAG2. Immunity (1995) 1.34
Endotoxin-macrophage interaction: post-translational regulation of tumor necrosis factor expression. J Immunol (1989) 1.32
Core antigen mutations of human hepatitis B virus in hepatomas accumulate in MHC class II-restricted T cell epitopes. Virology (1995) 1.32
Pregenomic RNA encapsidation analysis of eleven missense and nonsense polymerase mutants of human hepatitis B virus. J Virol (1991) 1.30
Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res (1999) 1.28
Dynamics of the macrophage plasma membrane. Annu Rev Microbiol (1979) 1.26
Dislocation after total hip arthroplasty. Arch Orthop Trauma Surg (1999) 1.25
Endotoxin tolerance: independent regulation of interleukin-1 and tumor necrosis factor expression. Infect Immun (1991) 1.24
A frequent, naturally occurring mutation (P130T) of human hepatitis B virus core antigen is compensatory for immature secretion phenotype of another frequent variant (I97L). J Virol (2000) 1.22
Mammographic appearances of male breast disease. Radiographics (1999) 1.20
Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circ Shock (1989) 1.19
The relationships between personal PM exposures for elderly populations and indoor and outdoor concentrations for three retirement center scenarios. J Expo Anal Environ Epidemiol (2001) 1.19
Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J Med Chem (1996) 1.18
Surgical anatomy of the mandibular ramus of the facial nerve in Chinese adults. Acta Anat (Basel) (1991) 1.18
cis rescue of a mutated reverse transcriptase gene of human hepatitis B virus by creation of an internal ATG. J Virol (1990) 1.17
Transcriptional and post-transcriptional mechanisms involved in the differential expression of LPS-induced IL-1 and TNF mRNA. Immunology (1991) 1.17
Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol (1999) 1.16
Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol (1997) 1.15
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J (1996) 1.14
Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem (1999) 1.13
Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene (1993) 1.12
Transcriptional inhibition of endotoxin-induced monokine synthesis following heat shock in murine peritoneal macrophages. J Leukoc Biol (1992) 1.12
Environmental estrogens: effects on cholesterol lowering and bone in the ovariectomized rat. J Steroid Biochem Mol Biol (1996) 1.10
Functional characterization of naturally occurring variants of human hepatitis B virus containing the core internal deletion mutation. J Virol (1998) 1.10
Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet (1994) 1.10
Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A (1997) 1.10
Gamma interferon: a central mediator in atherosclerosis. Inflamm Res (2005) 1.09
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem (1997) 1.09
Endotoxin tolerance: in vivo regulation of tumor necrosis factor and interleukin-1 synthesis is at the transcriptional level. Cell Immunol (1992) 1.08
Isolation of a Fusarium solani mutant reduced in cutinase activity and virulence. J Bacteriol (1986) 1.08
Protein kinase C-alpha and -epsilon modulate connexin-43 phosphorylation in human heart. J Mol Cell Cardiol (2001) 1.07
A defective interference-like phenomenon of human hepatitis B virus in chronic carriers. J Virol (1998) 1.07
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem (1997) 1.07
Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci (1995) 1.07
The mechanism of natural occurrence of two closely linked HBV precore predominant mutations. Virology (1995) 1.06
Small intestinal submucosa as a vascular graft: a review. J Invest Surg (1993) 1.05
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res (2000) 1.05
Selective estrogen receptor modulators and postmenopausal women's health. J Womens Health (1997) 1.04
Characterization of a mutant pancreatic eIF-2alpha kinase, PEK, and co-localization with somatostatin in islet delta cells. J Biol Chem (1999) 1.04
Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol (1999) 1.04
The transcription factor HNF1 acts with C/EBP alpha to synergistically activate the human albumin promoter through a novel domain. J Biol Chem (1994) 1.03
Biochemical effects of estrogen on articular cartilage in ovariectomized sheep. Osteoarthritis Cartilage (1997) 1.02
Neuroendocrine regulation of in vivo cytokine production and effects: I. In vivo regulatory networks involving the neuroendocrine system, interleukin-1 and tumor necrosis factor-alpha. J Neuroimmunol (1989) 1.02
Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res (1998) 1.01
Glucocorticoid effects in an endotoxin-induced rat pulmonary inflammation model: differential effects on neutrophil influx, integrin expression, and inflammatory mediators. Am J Respir Cell Mol Biol (1996) 1.01
Mercury-induced conformational changes and identification of conserved surface loops in plasma membrane aquaporins from higher plants. Topology of PMIP31 from Beta vulgaris L. J Biol Chem (1997) 1.00
Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry (1991) 1.00
Glucocorticoid-dependent and -independent mechanisms involved in lipopolysaccharide tolerance. Eur J Immunol (1991) 0.99
The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J Biol Chem (1989) 0.99
The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo. Leukemia (2012) 0.97
Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res (2001) 0.97
Heterogeneous loss of connexin43 protein in ischemic dog hearts. J Cardiovasc Electrophysiol (1999) 0.96
Overlapping evolutionary affinities revealed by comparison of amino acid compositions. Proc Natl Acad Sci U S A (1982) 0.96
Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J Virol (1997) 0.96
A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res (1994) 0.95
Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Cancer Res (1996) 0.95
Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest New Drugs (1996) 0.94
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res (2001) 0.93
A clinical and anatomical study of the location of the mental foramen in adult Chinese mandibles. Acta Anat (Basel) (1986) 0.93
In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother Pharmacol (1999) 0.92
Peripheral neuroblastomas in two dogs. J Vet Diagn Invest (1992) 0.92
Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol (1997) 0.92
The characterization and functional significance of plasma membrane Fc Receptors. CRC Crit Rev Microbiol (1978) 0.91
In vivo modulation of murine serum tumour necrosis factor and interleukin-6 levels during endotoxemia by oestrogen agonists and antagonists. Immunology (1995) 0.91
Congenital cardiac anomalies in calves. Vet Rec (1981) 0.91
Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther (1995) 0.90
Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer (1998) 0.90